Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
Stopped The study was terminated prior to a planned interim analysis based on lack of required efficacy in the first 32 participants enrolled.
Conditions
Interventions
- DRUG: Moxetumomab Pasudotox
Sponsor
MedImmune LLC